
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is poised for success in the coming years as they continue to expand their portfolio and offerings in the radiopharmaceutical space. With new and potentially lucrative partnerships in the works, such as with GE for Flyrcado, the company is positioning itself for increased revenue and growth. Additionally, their recent acquisitions, including LNTH-2501 and the diagnostic agent Pylarify, are expected to contribute significantly in the future. All of these factors, coupled with the company's strong financials, make Lantheus an attractive investment opportunity with potential for long-term success.
Bears say
Lantheus Holdings is showing positive revenue and EPS performance, but with a decline in pricing for their key product Pylarify, which could impact future revenue growth. There are potential growth opportunities in the pipeline, such as FDA approval for LNTH-2501, but it is contingent on resolving manufacturing issues. The current multiple of 14.5x P/E does not reflect the potential for future growth and the company's potential receipt of TPT status from the FDA could level the reimbursement playing field, but it remains uncertain at this point.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares